Detoxification of methylglyoxal by the glyoxalase system is required for glutathione availability and virulence activation in *Listeria monocytogenes*

Andrea Anaya-Sanchez, Ying Feng, John C. Berude, Daniel A. Portnoy

1 Graduate Group in Microbiology, University of California, Berkeley, Berkeley, California, United States of America, 2 Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, United States of America, 3 Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, California, United States of America

* portnoy@berkeley.edu

Abstract

*Listeria monocytogenes* is a Gram-positive, food-borne pathogen that lives a biphasic lifestyle, cycling between the environment and as a facultative intracellular pathogen of mammals. Upon entry into host cells, *L. monocytogenes* upregulates expression of glutathione synthase (*gshF*) and its product, glutathione (GSH), which is an allosteric activator of the master virulence regulator PrfA. Although *gshF* mutants are highly attenuated for virulence in mice and form very small plaques in host cell monolayers, these virulence defects can be fully rescued by mutations that lock PrfA in its active conformation, referred to as PrfA*. While PrfA activation can be recapitulated *in vitro* by the addition of reducing agents, the precise biological cue(s) experienced by *L. monocytogenes* that lead to PrfA activation are not known. Here we performed a genetic screen to identify additional small-plaque mutants that were rescued by PrfA* and identified *gloA*, which encodes glyoxalase A, a component of a GSH-dependent methylglyoxal (MG) detoxification system. MG is a toxic byproduct of metabolism produced by both the host and pathogen, which if accumulated, causes DNA damage and protein glycation. As a facultative intracellular pathogen, *L. monocytogenes* must protect itself from MG produced by its own metabolic processes and that of its host.

We report that *gloA* mutants grow normally in broth, are sensitive to exogenous MG and severely attenuated upon IV infection in mice, but are fully rescued for virulence in a PrfA* background. We demonstrate that transcriptional activation of *gshF* increased upon MG challenge *in vitro*, and while this resulted in higher levels of GSH for wild-type *L. monocytogenes*, the glyoxalase mutants had decreased levels of GSH, presumably due to the accumulation of the GSH-MG hemithioacetal adduct. These data suggest that MG acts as a host cue that leads to GSH production and activation of PrfA.
Author summary

*Listeria monocytogenes* is a facultative intracellular pathogen that dramatically changes gene expression upon infection of host cells by activating its major virulence regulator PrfA. The allosteric activator of PrfA is glutathione (GSH) that is produced by the bacterial glutathione synthase GshF. The requirement for GshF can be bypassed by PrfA mutations (PrfA\(^{\ast}\)) that are locked in their active form. In this study we screened for additional mutations that prevented virulence gene expression but were rescued by PrfA\(^{\ast}\). One of these mutations was in *gloA*, which encodes glyoxylase A, which detoxifies methylglyoxal (MG) in a glutathione-dependent fashion. In response to MG, *gloA* mutants up-regulated *gshF* mRNA but have lower levels of available GSH. These and other data suggest that MG production by the host activates *gshF* expression leading to elevated GSH levels and increased virulence gene expression.

Introduction

*Listeria monocytogenes* is a Gram-positive facultative intracellular pathogen and a significant cause of human disease, but is also an excellent model system to study basic aspects of host-pathogen interactions [1]. *L. monocytogenes* is an ubiquitous saprophyte found in soil, water and vegetation, and can contaminate a variety of food products leading to periodic outbreaks of disease [1,2]. Following ingestion by susceptible mammalian hosts, *L. monocytogenes* transitions into an intracellular pathogen largely by the transcriptional up-regulation of virulence gene expression [2,3].

In order to access its replicative niche in the host cytosol, *L. monocytogenes* secretes listeriolysin O (LLO), a pore-forming, cholesterol-dependent cytolysin that mediates disruption of the phagosome [3]. In the cytosol, *L. monocytogenes* up-regulates the expression and synthesis of the master virulence regulator PrfA, that directly regulates the transcription of nine virulence genes including ActA, a surface protein that mediates host actin polymerization and promotes movement and dissemination into neighboring cells [4]. PrfA is a member of the cAMP receptor protein (Crp) family of transcription factors that are allosterically regulated by small-molecule activators. Transcriptional activation of PrfA requires allosteric binding to glutathione (GSH) that is produced by *L. monocytogenes* glutathione synthase (GshF) [5]. *L. monocytogenes* strains that lack *gshF* are attenuated for virulence, but the requirement for glutathione can be bypassed by mutations that lock PrfA on its active conformation and are referred to as PrfA\(^{\ast}\) [5].

Although there is a comprehensive understanding of the intracellular life cycle of *L. monocytogenes*, less is known about the exact biological cue(s) sensed by this pathogen that drive the transition from extracellular to intracellular gene expression. Previous studies have shown PrfA activation *in vitro* by the addition of reducing agents [6], however, what *L. monocytogenes* senses *in vivo* remains unknown. Nonetheless, since GSH serves as an antioxidant and *gshF* is upregulated *in vivo*, we speculate that reactive oxygen species (ROS), reactive electrophilic species (RES) and/or reactive nitrogen species (RNS) may be inflicting redox stress leading to upregulation of GshF.

Methylglyoxal (MG) is a RES that is an ubiquitous byproduct of cellular metabolism and is produced by both bacteria and host cells [7,8]. MG reacts with arginine, lysine, and cysteine residues in proteins, resulting in the formation of advanced glycation end products (AGEs), which often leads to protein inactivation [7,9]. Additionally, MG modifies guanine bases, resulting in DNA damage and increased mutation rates [10,11]. This toxic metabolite can be
synthesized through enzymatic (methylglyoxal synthase) and non-enzymatic reactions [12]. While MG production can result from protein and lipid metabolism (Fig 1B), glycolysis is the most important source of endogenous MG (Fig 1A) [7]. Of note, *Mycobacterium tuberculosis* infected macrophages secrete up to 1.6 mM MG into culture media [13]. As a facultative intracellular pathogen, *L. monocytogenes* must protect itself from both endogenously produced MG and that produced by its host.

The major mechanism of protection from MG is mediated by the glyoxalase system (Fig 1C). Briefly, MG detoxification is initiated by the non-enzymatic reaction of this toxic metabolite with a low-molecular-weight thiol such as reduced glutathione (GSH) or bacillithiol, forming a hemithioacetal. This molecule is then transformed to S-lactoylglutathione by GloA. S-lactoylglutathione activates potassium efflux pumps that acidify the cytoplasm and confer protection against MG. GloB then transforms S-lactoylglutathione to D-lactate, recycling GSH in the process [15].

In order to better understand the biological cues sensed by *L. monocytogenes* upon entry into the host cytosol, we screened for small-plaque mutants that were rescued in a PrfA− background. This screen identified glyoxalase A, the first enzyme in the glyoxalase system (Fig 1C). *L. monocytogenes* gloA mutants were attenuated for plaque formation and in an IV mice model.
of infection. Virulence defects were fully rescued in a PrfA⁺ background. The presence of MG increased gshF mRNA and GSH levels in vitro, resulting in the activation of actA transcription. These data suggest that MG acts as a biological cue that leads to PrfA activation.

Results
A genetic screen identifies gloA as a small-plaque mutant rescued by PrfA⁺

We sought to identify genes other than gshF involved in L. monocytogenes virulence activation. L. monocytogenes is capable of spreading to neighboring cells, which is evidenced by its capacity to form plaques in tissue culture cell monolayers. The plaque assay is a straightforward and efficient method to screen for mutants defective in intracellular growth or cell-to-cell spread [16]. A himar-1 transposon library was used to screen for transposon insertions that caused a small-plaque phenotype in the L2 murine fibroblast cell line after 3 days of infection. A total of approximately 100,000 plaques were screened, 300 were initially picked, and 132 were further selected after the purification cycles, representing 34 genes. The selected small-plaque mutants had at least a 20% decrease in plaque size compared to wild-type L. monocytogenes. Transposon insertions were transduced into wild-type and PrfA⁺ backgrounds and compared using the plaque assay (Table 1). As the goal of the genetic screen was to better understand the cytosolic biological cues leading to PrfA activation, we were primarily interested in transposon mutations that could be rescued by PrfA⁺, which would suggest a role in L. monocytogenes virulence activation. As expected, insertions in gshF fulfilled this criteria [5], but we also identified an insertion in lmo2168 that was rescued in a PrfA⁺ background to within 10% of the plaque size of wild-type PrfA⁺ (Table 1). GloA (lmo2168) encodes glyoxalase A, also known as lactoylglutathione lyase, an enzyme required for MG detoxification (Fig 1).

Attenuated virulence of a gloA deletion mutant is fully rescued by PrfA⁺

To study the role of GloA-dependent MG detoxification in L. monocytogenes virulence activation, we generated an in-frame deletion of gloA in wild-type (ΔgloA) and PrfA⁺ (PrfA⁺/ΔgloA) genetic backgrounds and characterized the mutants for growth and infection dynamics (Figs 2 and 3). The gloA deletion mutant had a 55% plaque size relative to wild-type that, similar to the gloA transposon mutant, was fully rescued in a PrfA⁺ background. The plaque phenotype was also restored by complementation using an integration plasmid containing the gloA gene expressed from a pHyper promoter (ΔgloA + gloA; Fig 2A). Interestingly, the ΔgloA mutant had a negligible defect when cultured in broth and a small but significant difference at 5 hours-post infection of bone marrow-derived macrophage (BMM) when compared to wild-type L. monocytogenes (Fig 2B and 2C).

MG production is increased in toll-like receptor (TLR)-stimulated and IFN-γ activated macrophages [13,17]. We hypothesized that overnight treatment with PAM3CSK4, a TLR2 agonist, would stimulate BMMs and increase MG levels, affecting infection dynamics of ΔgloA L. monocytogenes that are impaired for MG detoxification. An intracellular growth defect was observed in the ΔgloA strain under these infection conditions, that was most evident at 8 hours post-infection and fully rescued by PrfA⁺ (Fig 2D), suggesting that exogenous MG (i.e. produced by stimulated host cells) represented the primary source of this toxic metabolite during L. monocytogenes infection. To further assess the relevance of MG detoxification in L. monocytogenes virulence, CD-1 mice were infected intravenously with 10⁵ CFU of each strain and CFUs were determined in the spleens and livers harvested 48 hours post-infection. The ΔgloA mutant presented a 3-log virulence attenuation compared to wild-type L. monocytogenes. The virulence defect was fully rescued in a PrfA⁺ background and
Table 1. Genes identified in small-plaque screen.

| Lmo number | LMRG number | # Hits<sup>a</sup> | Annotation | Background | Plaque size<sup>b</sup> | Background | Plaque size<sup>b</sup> |
|------------|-------------|--------------------|------------|------------|-------------------------|------------|-------------------------|
| 0201       | 02623       | 4                  | plcA       | wt         | 100 ± 1.20              | PrfA<sup>c</sup> | 109 ± 1.46              |
| 0202       | 02624       | 2                  | hly        | wt         | 24 ± 0.58               | PrfA<sup>c</sup> | 38 ± 0.84               |
| 0203       | 02625       | 6                  | mpl        | wt         | 36 ± 1.56               | PrfA<sup>c</sup> | 34 ± 0.69               |
| 0205       | 02627       | 6                  | plcB       | wt         | 23 ± 0.78               | PrfA<sup>c</sup> | 48 ± 1.31               |
| 0402       | 00095       | 1                  | hypothetical protein | wt | 81 ± 1.27 | PrfA<sup>c</sup> | 90 ± 1.04 |
| 0898       | 02322       | 1                  | hypothetical protein | wt | 74 ± 0.90 | PrfA<sup>c</sup> | 78 ± 1.27 |
| 0930       | 02029       | 1                  | yhl        | wt         | 50 ± 1.43               | PrfA<sup>c</sup> | 37 ± 1.51               |
| 0931       | 02030       | 16                 | lplA       | wt         | 28 ± 0.98               | PrfA<sup>c</sup> | 66 ± 0.92               |
| 0964       | 02063       | 1                  | yibH       | wt         | 56 ± 0.91               | PrfA<sup>c</sup> | 72 ± 1.19               |
| 0980       | 02080       | 1                  | yadH       | wt         | 64 ± 1.61               | PrfA<sup>c</sup> | 73 ± 1.41               |
| 1360       | 00810       | 20                 | folD       | wt         | 26 ± 1.15               | PrfA<sup>c</sup> | 32 ± 0.74               |
| 1372       | 00822       | 1                  | acoA       | wt         | 51 ± 0.80               | PrfA<sup>c</sup> | 54 ± 0.85               |
| 1490       | 00943       | 4                  | aroD       | wt         | 40 ± 1.41               | PrfA<sup>c</sup> | 37 ± 0.79               |
| 1523       | 01447       | 2                  | relA       | wt         | 36 ± 0.89               | PrfA<sup>c</sup> | 42 ± 0.97               |
| 1945       | 01092       | 2                  | ribU       | wt         | 54 ± 0.89               | PrfA<sup>c</sup> | 45 ± 1.19               |
| 2049       | 01199       | 1                  | hypothetical protein | wt | 44 ± 0.85 | PrfA<sup>c</sup> | 39 ± 1.26 |
| 2157       | 01675       | 1                  | secA       | wt         | 76 ± 1.75               | PrfA<sup>c</sup> | 69 ± 1.39               |
| 2168       | 01664       | 2                  | gloA       | wt         | 57 ± 0.73               | PrfA<sup>c</sup> | 104 ± 0.61              |
| 2194       | 01638       | 8                  | oppC       | wt         | 18 ± 0.36               | PrfA<sup>c</sup> | 22 ± 0.57               |
| 2195       | 01637       | 2                  | oppB       | wt         | 30 ± 1.22               | PrfA<sup>c</sup> | 39 ± 0.75               |
| 2196       | 01636       | 5                  | oppA       | wt         | 29 ± 0.68               | PrfA<sup>c</sup> | 33 ± 1.41               |
| 2215       | 01617       | 1                  | ABC transporter ATP-binding protein | wt | 70 ± 1.52 | PrfA<sup>c</sup> | 57 ± 1.05 |
| 2250       | 01581       | 1                  | arfl       | wt         | 33 ± 1.16               | PrfA<sup>c</sup> | 56 ± 0.77               |
| 2386       | 02731       | 1                  | yuiD       | wt         | 51 ± 0.85               | PrfA<sup>c</sup> | 48 ± 0.90               |
| 2448       | 01800       | 1                  | SsrA-binding protein | wt | 68 ± 1.07 | PrfA<sup>c</sup> | 74 ± 1.24 |
| 2473       | 01775       | 1                  | hypothetical protein | wt | 52 ± 1.04 | PrfA<sup>c</sup> | 54 ± 1.06               |
| 2474       | 01774       | 1                  | hypothetical protein | wt | 59 ± 1.54 | PrfA<sup>c</sup> | 54 ± 1.29               |
| 2510       | 01738       | 1                  | secA<sup>c</sup> | wt | 42 ± 1.17 | PrfA<sup>c</sup> | 47 ± 0.95               |
| 2545       | 01702       | 2                  | thrB       | wt         | 42 ± 1.08               | PrfA<sup>c</sup> | 42 ± 1.47               |
| 2546       | 01701       | 1                  | thrC       | wt         | 39 ± 1.29               | PrfA<sup>c</sup> | 37 ± 0.63               |
| 2748       | 01948       | 2                  | ybgG<sup>d</sup> | wt | 42 ± 0.92 | PrfA<sup>c</sup> | 36 ± 1.03               |
| 2770       | 01925       | 26                 | gshF       | wt         | 39 ± 0.93               | PrfA<sup>c</sup> | 107 ± 1.91              |
| 2843       | 01855       | 1                  | hypothetical protein | wt | 65 ± 1.31 | PrfA<sup>c</sup> | 61 ± 1.05               |
| 0201–0202  | 02623–02624 | 1                  | intergenic space | wt | 42 ± 1.00 | PrfA<sup>c</sup> | 39 ± 0.85               |

<sup>a</sup> Number of independent hits  
<sup>b</sup> Plaque size is an average of three independent replicates ± SEM (n = 40).  
<sup>c</sup> Transposon insertion was upstream secA gene.  
<sup>d</sup> Transposon insertion was upstream of the ybgG gene.

Complemented by insertion of an integrative plasmid containing the gloA gene expressed using a pHyper promoter (Fig 3).

Bacteria mainly use the glyoxalase system to detoxify MG, but may use alternative pathways as well [7,11]. To determine the relative contribution of the glyoxalase system in MG detoxification, we assessed *L. monocytogenes* strains for sensitivity against this toxic metabolite using a disk diffusion assay. The ΔgloA mutant was significantly more sensitive to MG than wild-type
Fig 2. In vitro phenotypes of glyoxalase mutants. (A) Plaque area measured 3 days post-infection as a percentage of wild-type. Mean and standard error of the mean (SEM) pooled from three independent experiments is shown (n = 30). (B) Broth growth curve of indicated *L. monocytogenes* strains grown in BHI medium at 37°C with shaking. Mean and standard deviation of three independent experiments is shown. BMM’s were infected at an MOI of 0.25 with *L. monocytogenes* without treatment (C) or treated with PAM3CSK4 (D) and intracellular CFU were enumerated at different time points. Data are mean and SEM of three technical replicates of three independent experiments. For both panels, statistical significance is shown for ΔgloA compared to wild-type *L. monocytogenes*. (E) Sensitivity to MG (20% v/v) as measured by growth inhibition in a disk diffusion assay as percentage of wild-type. Data are mean and SEM of at least three independent experiments. For all
and PrfA+ L. monocytogenes (Fig 2E). It is noteworthy that the PrfA+ mutation did not rescue the ΔgloA strain to MG sensitivity, suggesting that the virulence defect could not be entirely attributed to MG toxicity. Sensitivity to MG in ΔgloA was fully complemented by insertion of the gloA gene expressed from a phyper promoter.

Deletion of gloB results in attenuated virulence but to a lesser extent than gloA

The glyoxalase system is the major pathway used by cells for MG detoxification and is composed of two enzymes: glyoxalase A and B (Fig 1). A ΔgloA mutant was highly attenuated for virulence (Figs 2 and 3). To understand whether GloB was also critical for L. monocytogenes infection, we generated an in-frame deletion of the gloB gene and a double mutant that lacked both gloA and gloB. The ΔgloB mutant displayed a less attenuated virulence phenotype than ΔgloA, whereas the double mutant showed similar virulence defects (Figs 2 and 3). The plaque size of a ΔgloB mutant was approximately 80% relative to wild-type, while the ΔgloAΔgloB double mutant was 65% of wild-type (Fig 2A). Both L. monocytogenes strains grew similar to wild-type in BMMs, but only the ΔgloAΔgloB double mutant had a measurable defect for intracellular growth in PAM3CSK4-treated BMMs as observed for the ΔgloA mutant (Fig 2C–2D). The ΔgloB mutant had a 1-log virulence attenuation in murine infection and ΔgloAΔgloB presented the same 3-log attenuation observed for the gloA single mutant (Fig 3). An increased sensitivity to MG when compared to wild-type L. monocytogenes was observed for all the glyoxalase mutants, but was less pronounced for ΔgloB (Fig 2E). Plaque size and mice attenuation of the ΔgloB mutant were fully rescued in a PrfA+ background (Figs 2 and 3).
Cytoplasmic acidification protects bacteria from methylglyoxal-induced mutagenesis

MG is a highly reactive electrophile that interacts with DNA and has mutagenic effects [9,18,19]. To evaluate mutation rates as a result of MG exposure, we challenged *L. monocytogenes* strains with 1.2 mM MG in rich (BHI) and defined media (cLSM) and determined the frequency of rifampicin resistance. Mutation frequency consistently increased upon MG exposure compared to the non-treated groups in both growth conditions, but was more pronounced in defined media (Fig 4A and 4B). In defined media, mutants lacking gloA had at least an 8-fold increase in mutation frequency, that was also observed for the ΔgshF mutant but not for wild-type, PrfA+ or ΔgloB *L. monocytogenes*. The PrfA+ ΔgloA mutant had a lower mutation frequency compared to the ΔgloA mutant alone. Based on previous research [14], the ΔgloB mutant, unlike ΔgloA, should retain the capacity to activate potassium efflux pumps and acidify the bacterial cytoplasm leading to activation of a DNA damage response (Fig 1), and predictably, the gloB mutant had a lower mutation frequency.

Cytoplasmic acidification is sufficient for protection against MG in *B. subtilis* and *E. coli* most likely through the activation of a DNA damage response [10,13,14]. To assess if cytoplasmic acidification was sufficient to protect *L. monocytogenes* from MG-induced DNA damage, we determined rifampicin resistant derivatives upon MG exposure in media containing sodium benzoate, which decreases the pH of the bacterial cytoplasm by approximately 0.4 units and protects from MG-induced DNA damage [10,19]. Treatment with sodium benzoate decreased mutation frequency upon MG exposure to levels similar to the non-treated groups in both rich and defined media (Fig 4A and 4B), indicating that cytoplasmic acidification is protective against MG induced mutagenesis in *L. monocytogenes*.

![Fig 4. Mutation rates in *L. monocytogenes* glyoxalase mutants.](https://doi.org/10.1371/journal.ppat.1009819.g004)
Methylglyoxal increases gshF mRNA but lowers glutathione availability in glyoxalase mutants

The glyoxalase system detoxifies MG through two sequential enzymatic reactions. First, GSH and MG spontaneously form a hemithioacetal (Fig 1). Previous studies have shown that impairment in MG detoxification leads to decreased GSH availability in both mammalian and bacterial cells [7,10,14]. Since PrfA activation is dependent on the intracellular GSH levels, maintaining elevated concentrations is critical for *L. monocytogenes* to activate expression of virulence genes. We hypothesized that the glyoxalase mutants would have lower available intracellular levels of GSH, therefore, attenuated virulence. To test this hypothesis, we measured *L. monocytogenes* GSH concentration in wild-type, ΔgloA and ΔgloB strains at different time points post-MG exposure. We observed significantly lower available intracellular GSH at 15 minutes post-MG exposure in all strains (Fig 5A), however, by 30 minutes an increase in intracellular glutathione was observed. While the glyoxalase mutants reached GSH levels similar to the untreated wild-type *L. monocytogenes* at 30- and 60-minutes post-challenge, a significant increase was observed for the wild-type bacteria challenged with high amounts of MG (Fig 5A). These data indicated that although MG exposure immediately lowers available intracellular GSH in *L. monocytogenes*, it results in higher GSH concentration at later time points in the wild-type bacteria, but not in the glyoxalase mutants.

The capacity of bacteria to respond to redox stress is central for many cellular processes and survival. Antioxidants such as GSH are crucial for maintaining redox homeostasis. Previous studies have shown that upon oxidative stress, transcriptional regulators such as Spx in *B. subtilis* and CodY in *S. thermophilus* are induced and lead to upregulation of several genes including gshF and its analogue bshA, B and C [11,20,21]. We hypothesized that MG-induced oxidative stress functions as a metabolic cue that leads to upregulation of gshF expression in *L. monocytogenes*. To assess the expression of gshF, we performed real time-quantitative PCR to measure gshF mRNA levels upon MG exposure in defined media and during BMM infection. In defined media, gshF mRNA levels increased upon treatment with MG in all the *L. monocytogenes* strains tested, but was elevated in the gloA and gloB mutants (Fig 5B). During BMMs infection, gshF mRNA levels were also increased in the glyoxalase mutants compared to wild-type (Fig 5D). Consistent with the previous observations of increased gshF mRNA levels and higher intracellular GSH levels, we observed higher mRNA levels of actA upon MG challenge *in vitro* in wild-type *L. monocytogenes*, but not in the glyoxalase mutants (Fig 5C). Taken together, these data strongly suggest that MG toxicity induces expression of *L. monocytogenes* glutathione synthase and increases intracellular GSH as well.

Discussion

The results of this study showed that *L. monocytogenes* gloA mutants are hyper-sensitive to exogenous MG toxicity *in vitro* and highly attenuated for virulence *in vivo*. Importantly the *in vivo* defect was fully rescued by a mutation in the master virulence regulator that locks it in its active conformation (PrfA*′*). These data suggest that the virulence defect of gloA mutants is at least partially due to lack of PrfA activation. Since PrfA is allosterically activated by GSH and GloA mediates MG detoxification by conjugation with glutathione, the results of this study suggest that gloA mutants are avirulent because of glutathione depletion and the consequent lack of PrfA activation. However, the PrfA*′* mutation did not rescue *L. monocytogenes* from MG lethality *in vitro* and the gloB deficient bacteria had less virulence attenuation than gloA mutants. These data suggest that some of the attenuation may be due to MG sensitivity. We also showed that MG initially depletes bacterial GSH levels and activates gshF gene expression, resulting in higher GSH levels for the wild-type bacteria but not for the glyoxalase mutants.
Methylglyoxal detoxification in *Listeria monocytogenes*
that are unable to recycle GSH used for MG detoxification. This suggests that MG is among the biological cues leading to glutathione production, PrfA activation and virulence.

The glyoxalase system is composed of two enzymes (GloA and GloB) that act sequentially to detoxify MG. The glyoxalase system is crucial for MG detoxification in L. monocytogenes as was evident by the significant increase in sensitivity to this toxic metabolite when either or both glyoxalase enzymes were missing. However, while the ΔgloA mutant was 3-logs less virulent in mice, the ΔgloB mutant was only 1-log less virulent. Analysis of mutation frequencies of the glyoxalase mutants revealed elevated mutation frequency in response to MG for ΔgloA but not for ΔgloB. Mutation rates were restored to wild-type levels in the ΔgloA mutant upon cytoplasmic acidification by addition of sodium benzoate a method used in previous studies [11,14]. Acidification of the cytosol is mediated by the enzymatic product of GloA, S-lactoylglutathione, which activates potassium efflux pumps and results in the exchange of protons that decrease cytoplasmic pH (see Fig 1). Acidification of the bacterial cytosol results in activation of DNA damage responses and probably has other protective effects as well [11,14,19]. In ΔgloB mutants, the formation of S-lactoylglutathione by GloA still occurs, leading to lower cytoplasmic pH and less DNA damage [14,15]. It is likely that the ΔgloB mutant was more tolerant to MG due to the functional activation of potassium efflux pumps and protective cytoplasmic acidification. Unlike the ΔgloA strain, which was probably killed by MG damage, protection by potassium efflux pumps allowed the ΔgloB strain to endure MG and activate alternative detoxification pathways [7,20,22]. However, since GloB converts S-lactoylglutathione to glutathione and D-lactate, the ΔgloB mutant also had less available glutathione (Fig 5A) which likely leads to less PrfA activation and attenuated virulence.

It is hard to reconcile why a PrfA+ background fully rescued the ΔgloA mutant given that the ΔgloB mutant had the same GSH levels, at least in vitro, suggesting that virulence attenuation is not entirely due to GSH depletion. Notably, while the PrfA+ ΔgloA mutant had the same sensitivity to MG as the ΔgloA strain by disk diffusion, it had a lower MG-induced mutation frequency than the ΔgloA mutant. We hypothesize that PrfA activation protects the ΔgloA mutant from MG-induced DNA damage, although the mechanism and genes involved await further exploration. If our hypothesis is correct, it suggests that MG leads to PrfA activation and that activated PrfA not only mediates expression of the known virulence genes, but also mediates the bacterial response to MG toxicity and perhaps other host-derived stressors. Our lab continues to explore MG-induced DNA-damage and the possible roles played by PrfA activation.

MG is a RES that causes oxidative stress through increased generation of ROS and protein glycation [23–25]. L. monocytogenes produces this toxic byproduct of metabolism; thus, it must protect itself from MG produced by its cellular processes and that of its host. The fact that the glyoxalase mutants grew normally in broth but had a defect for growth in TLR-activated macrophages and in mice, suggests that host-derived MG imposes the major threat to bacteria during its intracellular growth, although we cannot rule out that changes in L. monocytogenes metabolism may also play a role. TLRs are pattern recognition receptors that upon stimulation, orchestrate an immune response by activating multiple signaling pathways that
result in a variety of genetic and metabolic changes [25], including increased glycolysis leading to increases in MG [17,26,27]. Activated macrophages not only increase MG production, they also down-regulate expression of their own glyoxalase enzymes, which may contribute to the inflammatory response [28] and may suggest a role for MG as an antimicrobial strategy.

Upon infection, *L. monocytogenes* faces numerous stressors. The most striking finding of our study is that upon MG stress *in vitro*, *gshF* transcription is activated, suggesting that MG is one of the metabolic and redox cues sensed by this pathogen *in vivo*. Accordingly, glyoxalase mutants had higher levels of *gshF* mRNA upon infection compared to wild-type *L. monocytogenes*. Our working model is that *L. monocytogenes* encounters MG in high quantities in the host cytosol and that stress caused by MG, and probably other ROS and RES, activates transcriptional regulators such as Spx that induce *gshF* transcription [11,21]. Indeed, a recent study reported that in *L. monocytogenes*, SpxA1 activated *gshF* transcription [27]. The results reported in this study suggest that RES and ROS encountered in the cytosol might be the host cues recognized by this pathogen to sense their entry into the host cell. Whether MG is the most prevalent RES and redox stress experienced in the cytosol of mammalian cells remains to be determined. Further studies on redox cues by which intracellular bacteria sense their host will help better understand how bacteria sense their environment and regulate virulence genes in response.

**Methods**

**Ethics statement**

All animal work was done in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and university regulations. Protocols were reviewed and approved by the Animal Care and Use Committee at the University of California, Berkeley AUP 2016-05-8811.

**Bacterial cultures and strains**

The parental strain for all *L. monocytogenes* strains used in this study (S1 Table) is 10403S. Bacteria were cultivated overnight at 37˚C shaking in Brain-Heart Infusion (BHI; BD) with streptomycin (GoldBio) unless otherwise stated. All *E. coli* strains (S2 Table) were grown in Luria broth (LB) at 37˚C shaking. Antibiotics were used at the following concentrations: streptomycin (200 μg/mL), erythromycin (1 μg/mL), carbenicillin (100 μg/mL) and chloramphenicol (7.5 μg/mL for *L. monocytogenes*; 10 μg/mL for *E. coli*). For broth growth curves, overnight cultures were diluted in 35 mL of fresh BHI to an initial optical density at 600 nm (OD600) of 0.05. Bacteria were cultured at 37˚C with shaking and growth was measured spectrophotometrically every hour [29].

For the generation of transposon libraries, electro-competent *L. monocytogenes* were prepared, and *himar-1* transposon mutagenesis was performed as described previously [30]. Transposon insertion sites were identified [30] and mapped to the 10403S genome. Transposons in *L. monocytogenes* were introduced into a wild-type and PrfA [31] background by transduction using the phage U153 as described previously [31]. *Himar-1* transposon transduction was selected on erythromycin (Sigma-Aldrich) after two days. Single colonies were sequenced for verification.

**Cloning and plasmid construction**

Deletions of genes were performed by allelic exchange using primers listed in S3 Table and the pKSV7 plasmid [32]. Briefly, constructed pKSV7 plasmids were transformed into XL1 Blue
and SM10 *E. coli*, recovered on LB agar plates containing carbenicillin (Sigma-Aldrich) and conjugated into *L. monocytogenes* on non-selective BHI agar. *L. monocytogenes* carrying the knock-out plasmid were selected on BHI containing streptomycin and chloramphenicol at 30˚C and re-streaked at 42˚C three consecutive times on BHI containing the same antibiotics to select for chromosomal integration. This selected strain was serially passaged at 30˚C shaking to facilitate loss of pKSV7. Mutants that lost the plasmid were identified by patch-plating methods and confirmed by PCR and Sanger sequencing [33]. The *gloA* complementation vector was constructed as previously described [34] in a pPL2 plasmid using a Phyper promoter. The plasmid was transformed into XL-Blue and SM10 *E. coli*. Following confirmation by Sanger sequencing, it was conjugated into wild-type and ΔgloA *L. monocytogenes*.

**Plaque screen and assay**

The mouse L2 fibroblast cell line was cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) supplemented with 10% Fetal Bovine Serum (FBS; Seradigm), 1% sodium pyruvate, 1% L-glutamine and 1% penicillin-streptomycin (Corning). L2 cells were grown in T75 flasks at 37˚C and split once cells were confluent (every 3–4 days). In all experiments, L2 cells were plated overnight so that they were confluent the day of the infection. A himar-1 transposon library composed of approximately 10,000 *L. monocytogenes* mutants [30] was used to screen for transposon insertions that caused a small-plaque phenotype. For the initial screening for small-plaque mutants, 4 x 10^6 L2 cells were seeded in 100-mm petri dishes and infected at an MOI of 0.1. The plaque assay was performed as previously described [16]. L2 cells are commonly used to perform this particular assay because they generate highly homogeneous and reproducible plaques [16]. Plaques were imaged 72 hours post-infection and small plaques were selected. Selected small plaque mutants were purified by repeating the plaque-formation assay until the plaque phenotype was completely homogenous. Transposon mutants were sequenced and transduced into different genetic backgrounds. For routine plaque assays, six-well plates were seeded with 1.2 x 10^6 L2 cells per well and infected at an MOI of 0.1. The plaque assay was performed as described previously [16]. Plaques were imaged 72 hours post-infection and plaque area was quantified using ImageJ software. Each experiment represents an average of the area of ten plaques per strain as a percentage of wild-type *L. monocytogenes*. Groups were statistically compared using an unpaired Student’s *t*-test.

**Intracellular growth curves**

Macrophage growth curves were performed as previously described [35]. Bone marrow derived macrophages (BMMs) were derived from bone marrow of C57BL/6 mice (Jackson Laboratory) and cultivated in DMEM medium containing 10% CSF (from M-CSF-producing 3T3 cells), 20% FBS, 1% L-glutamine, 1% sodium pyruvate and 14 mM 2-mercaptoethanol (Gibco). A total of 3 x 10^6 BMMs were plated in 60 mm petri dishes containing 14 12 mm glass coverslips in each dish. For indicated experiments, BMMs were seeded overnight with medium containing PAM3CSK4 (Invivogen) at a final concentration of 100ng/mL. These dishes were infected the next day at an MOI of 0.25 for 30 minutes, washed twice with sterile PBS and 50 μg/mL gentamicin (Sigma-Aldrich) was added 1-hour post-infection. Three coverslips were removed at each time point, rigorously mixed in sterile water and plated on LB agar with streptomycin. Each experiment represents the average of three coverslips per time point per strain.

**Virulence in mice**

Eight-week-old female CD-1 mice (Charles River Laboratories) were infected intravenously via the tail vein with 1 x 10^5 CFU of *L. monocytogenes* strains in 200 μL of sterile PBS as
described [31]. Forty-eight hours post-infection, mice were euthanized, and spleens and livers were harvested, homogenized in 0.1% NP-40 (Sigma-Aldrich) in water, and plated on LB agar with streptomycin. Groups were statistically compared using an unpaired Student’s t-test.

**Disk-diffusion assay**

Disk-diffusion assays were performed similarly to methods described previously [31,33]. 1 x 10^6 CFUs from overnight cultures grown at 37˚C shaking were mixed in 4 mL of top agar (0.8% NaCl and 0.8% bacto-agar) and spread evenly on BHI plates containing streptomycin. Whatman paper disks containing 20 μL of 20% MG (Sigma-Aldrich) were placed on top of the cooled agar. The zone of inhibition was measured 18–24 hours after incubation at 37˚C. Total inhibition area as percentage of wild-type *L. monocytogenes* is presented from at least three independent experiments. Statistical significance was determined using an unpaired Student’s t-test.

**Rifampicin mutagenesis assay**

Mutation frequency in rifampicin was determined using similar previously described methods [36]. *L. monocytogenes* strains were grown at 37˚C shaking in fresh BHI or defined media (cLSM) [37], containing 1.2 mM MG or 1.2 mM MG plus 30 mM Sodium benzoate (Sigma-Aldrich). The next day, OD_{600} was measured for each strain and 100 μL of overnight cultures were plated in LB agar plates containing 5 μg/mL of rifampicin (Sigma-Aldrich). CFUs were counted after a 24-hour incubation at 37˚C. Mutation frequency was calculated as the ratio between CFUs enumerated in the LB agar plates containing rifampicin and the total number of *L. monocytogenes* plated. Data represents the average of two technical replicates from three independent experiments.

**Glutathione assay**

Reduced glutathione (GSH) concentrations were measured by using a commercial kit supplied by Sigma-Aldrich (CS0260) according to the manufacturer’s specifications. Briefly, overnight *L. monocytogenes* cultures were diluted to an OD_{600} of 0.1 in 35 mL of fresh defined media and grown at 37˚C shaking. After two hours, 10 OD_{600} were transferred to 15 mL Falcon tube and 0.4 or 1.2 mM of MG was added to the indicated cultures. The media was supplemented with cysteine doubling the amount of MG added (0.8 mM or 2.2 mM) 15 minutes after the addition of MG. For the untreated cultures a total of 0.8 mM cysteine was added. Bacteria in the Falcon tube were washed twice in sterile PBS and resuspended in 200 μL of 5% 5-Sulfosalicylic Acid. Bacteria were lysed 0.1 mm-diameter silica-zirconium beads and 10 μL were used for the kit’s working reaction. Samples were taken at 15, 30 and 60 minutes post-challenge with MG. Absorbance at 412 nm was measured using a plate reader (Infinite M1000 PRO, TECAN). GSH concentrations as a percentage of wild-type without MG challenge are an average of two technical replicates from three independent experiments.

**Quantitative RT-PCR of bacterial transcripts**

Transcript analysis in defined media was performed as described previously [38]. Overnight cultures were diluted 1:10 in 5 mL of fresh cLSM. When the culture reached mid-log growth, 0.4 mM or 1.2 mM MG were added to the cultures. *L. monocytogenes* strains were harvested 15 minutes post-MG addition at an OD_{600} of 0.5. Transcript analysis during infection was performed as previously described [5]. Briefly, 3x10^7 BMMs were plated in 150 mm TC-treated dishes and infected with an MOI of 10. One-hour post-infection the cells were washed with
PBS and media containing gentamicin (50 μg/mL) was added. Four hours post-infection the cells were washed with PBS and lysed in 5 mL of 0.1% NP-40. RNAProtect Bacteria Reagent (Qiagen) was used to rinse the dishes, which was combined with the lysate. Bacteria were collected by centrifugation. RNA from bacteria harvested from either cLSM or BMMs was obtained using Quick RNA fungal/bacterial Miniprep from Zymo Research (R2014). Obtained nucleic acids were treated with TURBO DNase (Invitrogen) and concentrated with the RNA clean and concentrator kit from Zymo Research (R2017). RNA was reverse transcribed with iScript (Bio-RAD) and quantitative PCR (qPCR) was performed using SYBR FAST (Kapa Biosystems). Primers used for qPCR are listed in S3 Table.

Statistical analysis
Data were analyzed using GraphPad Prism 8. * indicates P < 0.05; ** indicates P < 0.01, *** indicates P < 0.001, **** indicates P < 0.0001.

Supporting information
S1 Table. L. monocytogenes strains used in this study. (DOCX)
S2 Table. E. coli strains used in this study. (DOCX)
S3 Table. Oligonucleotide primers used in this study. (DOCX)

Author Contributions
Conceptualization: Andrea Anaya-Sanchez, Daniel A. Portnoy.
Data curation: Andrea Anaya-Sanchez.
Formal analysis: Andrea Anaya-Sanchez, Ying Feng, John C. Berude.
Funding acquisition: Daniel A. Portnoy.
Investigation: Andrea Anaya-Sanchez, Ying Feng, John C. Berude.
Methodology: Andrea Anaya-Sanchez, Ying Feng, John C. Berude.
Project administration: Andrea Anaya-Sanchez, Daniel A. Portnoy.
Resources: Andrea Anaya-Sanchez.
Supervision: Andrea Anaya-Sanchez, Daniel A. Portnoy.
Validation: Andrea Anaya-Sanchez.
Visualization: Andrea Anaya-Sanchez.
Writing – original draft: Andrea Anaya-Sanchez.
Writing – review & editing: Andrea Anaya-Sanchez, Ying Feng, John C. Berude, Daniel A. Portnoy.

References
1. Radoshevich L, Cossart P. Listeria monocytogenes: towards a complete picture of its physiology and pathogenesis. Nat Rev Microbiol [Internet]. 2018 Jan 27; 16(1):32–46. Available from: http://www.nature.com/articles/nrmicro.2017.126 https://doi.org/10.1038/nrmicro.2017.126 PMID: 29176582
2. Freitag NE, Port GC, Miner MD. Listeria monocytogenes—from saprophyte to intracellular pathogen. Nat Rev Microbiol [Internet]. 2009 Sep 3; 7(9):623–8. Available from: http://www.nature.com/articles/nrmicro2171 https://doi.org/10.1038/nrmicro2171 PMID: 19648949

3. de las Heras A, Cain RJ, Bielecka MK, Vázquez-Boland JA. Regulation of Listeria virulence: PrfA master and commander. Curr Opin Microbiol [Internet]. 2011 Apr; 14(2):118–27. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1369527411000178 https://doi.org/10.1016/j.mib.2011.01.005 PMID: 21388662

4. Vázquez-Boland JA, Kuhn M, Berche P, Chakraborty T, Domínguez-Bernal G, Goebel W, et al. Listeria Pathogenesis and Molecular Virulence Determinants. Clin Microbiol Rev [Internet]. 2001 Jul 1; 14(3):584–640. Available from: https://cmr.asm.org/content/14/3/584 https://doi.org/10.1128/CMR.14.3.584-640.2001 PMID: 11432815

5. Reniere ML, Whiteley AT, Hamilton KL, John SM, Lauer P, Brennan RG, et al. Glutathione activates virulence gene expression of an intracellular pathogen. Nature [Internet]. 2015 Jan 8; 517(7533):170–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25567281

6. Portman JL, Dubensky SB, Peterson BN, Whiteley AT, Portnoy DA. Activation of the Listeria monocytogenes Virulence Program by a Reducing Environment. Miller JF, editor. MBio [Internet]. 2017 Nov 8; 8(5). Available from: http://mbio.asm.org/lookup doi/10.1128/mBio.01595-17 PMID: 29042499

7. Almagro F, Aebischer M, Magistretti PJ. Methylglyoxal, the dark side of glycolysis. Front Neurosci [Internet]. 2015 Feb 9:9. Available from: http://journal.frontiersin.org/Article/10.3389/fnins.2015.00023/abstract PMID: 25668184

8. Lee C, Park C. Bacterial Responses to Glyoxal and Methylglyoxal: Reactive Electrophilic Species. Int J Mol Sci [Internet]. 2017 Jan 17; 18(1):169. Available from: http://www.mdpi.com/1422-0067/18/1/169 https://doi.org/10.3390/ijms18010169 PMID: 28106725

9. Cooper RA. Metabolism of Methylglyoxal in Microorganisms. Annu Rev Microbiol [Internet]. 1984 Oct; 38(1):49–68. Available from: http://www.annualreviews.org/doi/10.1146/annurev.mi.38.100184.000405 PMID: 6936858

10. Chi BK, Gronau K, Mäder U, Hessling B, Becher D, Antelmann H. -Bacillithiolation Protects Against Hypochlorite Stress in Bacillus subtilis as Revealed by Transcriptomics and Redox Proteomics. Mol Cell Proteomics [Internet]. 2011 Nov; 10(11):M111.009506. Available from: http://mcponline.org/lookup doi/10.1074/mcp.M111.009506 PMID: 21749987

11. Chandrangsu P, Dusi R, Hamilton CJ, Helmann JD. Methylglyoxal resistance in B. subtilis: contributions of bacillithiol-dependent and independent pathways. Mol Microbiol [Internet]. 2014 Feb; 91(4):706–15. Available from: http://dx.doi.org/10.1111/mmi.12489 PMID: 24330391

12. Kalapos MP. Methylglyoxal in living organisms. Toxicol Lett [Internet]. 1999 Nov; 110(3):145–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378427499001605 https://doi.org/10.1016/S0378-4274(99)00160-5 PMID: 10597025

13. Rachman H, Kim N, Ulrichs T, Baumann S, Pradi L, Eddine AN, et al. Critical Role of Methylglyoxal and AGE in Mycobacteria-Induced Macrophage Apoptosis and Activation. Unutmaz D, editor. PLoS One [Internet]. 2006 Dec 20; 1(1):e29. Available from: https://doi.org/10.1371/journal.pone.0000029 PMID: 17183656

14. Ozymak E, Black SS, Walker CA, MacLean MJ, Bartlett W, Miller S, et al. The critical role of S-lactoyl-glutathione formation during methylglyoxal detoxification in Escherichia coli. Mol Microbiol [Internet]. 2010 Dec 29; 78(6):1577–90. Available from: https://doi.org/10.1111/j.1365-2958.2010.07426.x PMID: 21143325

15. Booth IR, Ferguson GP, Miller S, Li C, Gunasekera B, Kinghorn S. Bacterial production of methylglyoxal: a survival strategy or death by misadventure? Biochem Soc Trans [Internet]. 2003 Dec 1; 31(6):1406–8. Available from: https://portlandpress.com/biochemsoctrans/article/31/6/1406/64455/Bacterial-production-of-methylglyoxal-a-survival https://doi.org/10.1042/bst0314106 PMID: 14641075

16. Sun AN, Camilli A, Portnoy DA. Isolation of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread. Infect Immun [Internet]. 1990 Nov; 58(11):3770–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2172168 https://doi.org/10.1128/IAI.58.11.3770-3778.1990 PMID: 2172168

17. Dhananjayan K, Gunawardena D, Heam N, Sonntag T, Moran C, Gyengesi E, et al. Activation of Macrophages and Microglia by Interferon-γ and Lipopolysaccharide Increases Methylglyoxal Production: A New Mechanism in the Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus? J Alzheimer’s Dis [Internet]. 2017 Jul 17; 59(2):467–79. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-161152 PMID: 28582854

18. Dorado L, Ruiz Montoya M, Rodríguez Mellado JM. A contribution to the study of the structure-mutagenicity relationship for α-dicarbonyl compounds using the Ames test. Mutat Res Mol Mech Mutagen...
34. Lauer P, Chow MYN, Loessner MJ, Portnoy DA, Calendar R. Construction, Characterization, and Use of Two Listeria monocytogenes Site-Specific Phage Integration Vectors. J Bacteriol [Internet]. 2002 Aug 1; 184(15):4177–86. Available from: https://doi.org/10.1128/JB.184.15.4177-4186.2002 PMID: 12107135

35. Portnoy DA, Jacks PS, Hinrichs DJ. Role of hemolysin for the intracellular growth of Listeria monocytogenes. J Exp Med [Internet]. 1988 Apr 1; 167(4):1459–71. Available from: https://rupress.org/jem/article/167/4/1459/24021/Role-of-hemolysin-for-the-intracellular-growth-of PMID: 2833557

36. Morse R, O' Hanlon K, Virji M, Collins MD. Isolation of rifampin-resistant mutants of Listeria monocytogenes and their characterization by rpoB gene sequencing, temperature sensitivity for growth, and interaction with an epithelial cell line. J Clin Microbiol [Internet]. 1999 Sep; 37(9):2913–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449475 https://doi.org/10.1128/JCM.37.9.2913-2919.1999 PMID: 10449475

37. Whiteley AT, Pollock AJ, Portnoy DA. The PAMP c-di-AMP Is Essential for Listeria monocytogenes Growth in Rich but Not Minimal Media due to a Toxic Increase in (p)pGpp. Cell Host Microbe [Internet]. 2015 Jun; 17(6):788–98. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1931312815002103 https://doi.org/10.1016/j.chom.2015.05.006 PMID: 26028365

38. Burke TP, Loukitcheva A, Zemansky J, Wheeler R, Boneca IG, Portnoy DA. Listeria monocytogenes is resistant to lysozyme through the regulation, not the acquisition, of cell wall-modifying enzymes. J Bacteriol [Internet]. 2014 Nov; 196(21):3756–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25157076 https://doi.org/10.1128/JB.02053-14 PMID: 25157076